Duncan Steele is the Deputy Director and Strategic Lead for enteric vaccines in the Enteric and Diarrheal Diseases team of the Bill & Melinda Gates Foundation. He is responsible for an integrated portfolio of vaccine research and development and for implementation strategies for the control of diarrhea and enteric fever in vulnerable populations in endemic countries. He coordinates teams across Vaccine Development and Vaccine Delivery for improved and new vaccines against rotavirus, cholera, typhoid fever, Shigella spp. and Hepatitis E virus.
Before starting at the foundation in October 2011, Dr. Steele was at PATH, a global health non-profit organization, where he worked across multiple diarrhea vaccine-related programs, including the Gavi-funded Rotavirus Vaccine Program focused on disease burden and clinical trials in Africa and Asia; and in vaccine development for new alternative rotavirus vaccines; and for vaccines against ETEC and Shigella. Previously, as a scientist at the Initiative for Vaccine Research, Department of Immunization, Vaccines and Biologicals, World Health Organization, Steele was responsible for the diarrheal disease vaccines portfolio, where he coordinated a global strategic agenda for vaccine research for the major diarrheal and enteric diseases.
Dr. Steele is a South African trained microbiologist with extensive experience in virology and microbiology, especially for diarrheal diseases, and was based at MEDUNSA, now Sefako Makgatho Health Sciences University where he has kept a relationship, continuing to mentor postgraduate students. In 1996, he established the world recognized South African MRC-funded Diarrheal Pathogens Research Unit which pioneered rotavirus research on the continent and developed collaborations with African researchers which continues today. His students and mentees are scattered across the African continent, many leading their own research groups. Steele is the author of more than 325 scientific publications on diarrheal diseases, epidemiology, clinical research and vaccine development.
